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A B S T R A C T
The effects of cisapride (10 mg three times daily) on the stool evacuation characteris-
tics, laxative consumption (symptom diary) and motility pattern (rectoanal manometry)
were assessed in patients with chronic idiopathic constipation who fulfilled Rome II cri-
teria. After a 14-day basal period on a diet rich in fiber (phase I), patients were treated
with placebo (n=20) or cisapride (n=19) (phase II). Anorectal manometry was performed
at the end of each phase. The study was controlled, randomized and double blind. Side
effects related to the use of cisapride were noted and found to be mild. Cisapride and
placebo increased stool frequency from 4 (1–11) to 7 (14–12) (p<0.001) and from 4 (2–10)
to 6 (2–11) (p<0.05) per week, respectively. Straining was decreased from 69.0% to 39.7%
in the cisapride (p<0.0001) group, and from 79% to 35% (p<0.0001) in the placebo
group. Both cisapride and placebo decreased the feeling of incomplete evacuation from
91.7% to 37.5% (p<0.0001) and from 82.7% to 39.2% (p<0.0001), respectively. Cisapride
reduced the need of laxatives and showed a tendency to normalize stool consistency but
did not influence any other symptom or bowel motility parameter.
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Introduction
Constipation is one of the most fre-
quent symptoms in gastroentrology1. Sym-
ptoms compatible with constipation are
found in 3%–20% of the population, and
the prevalence increases to 20%–25% in
the elderly2–4. Although physicians often
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focus mainly on the infrequency of bowel
movements in the definition of constipa-
tion, patients have a broader set of com-
plaints5. Conventionally, constipation may
be defined by three parameters: symp-
toms, measurements of defecation, and
physiologic measurements6.
Attempts to characterize a common
underlying motor abnormality have led to
disappointing conclusions. Investigations
report either increased or reduced, and
even normal intraluminal pressure chan-
ges of the sigmoid colon, and the same re-
sults are reported regarding the reactiv-
ity of the internal anal sphincter to rectal
distention7,8. The differences in findings
could be the result of a poor definition of
constipation and heterogeneity of the pa-
tients examined9. In most cases, consti-
pation can be treated with dietary manip-
ulation, simple laxatives or enemas1.
There is a group of patients in whom
medicamentous treatment is unsatisfac-
tory and where stimulant laxatives quick-
ly lose their effect and may cause myen-
teric plexus damage10. One approach to
the management of chronic constipation
consists of stimulation, as physiological
as possible, of the intestinal motility.
Cisapride is a benzodiazepine that has
been developed as a prokinetic directed
primarily to the upper bowel. It has also
been extensively used in the treatment of
constipation, the results being quite equi-
vocal, and concerns about its safety cau-
sed it to be withdrawn from the market in
the USA in July 200011–21.
The aim of this study was to deter-
mine the efficacy of cisapride as short-
term therapy for chronic idiopathic con-
stipation.
Patients and Methods
The study included two phases per-
formed over 6 weeks. Phase I termed
baseline phase lasted two weeks and was
followed by four-week treatment with pla-
cebo or cisapride administered in a ran-
domized and double-blind manner (phase
II). Throughout the study, patients were
encouraged to take a fiber-rich diet.
A questionnaire was used to define the
number of stools per week without any
treatment, and to detect the occurrence of
abdominal distension, straining at stools,
pain on defecation, hard stools, absence
of need to defecate, and need to maneuver
to expel stool.
During the study (phases I and II) pa-
tients kept a symptom diary in which
they could report each bowel movement,
consistency of stool according to the Bris-
tol Stool Form Scale, straining at defeca-
tion, and sensation of incomplete evacua-
tion if present. They could also report
laxative or other drug intake and side ef-
fects during the treatment phase. Patients
older than 18 with 3 or fewer spontane-
ous bowel movements per week or a com-
bination of two of the three symptoms
(straining at defecation, lumpy and/or hard
stools, and incomplete evacuation over at
least two years) were encouraged to enter
the baseline phase unless they met the
exclusion criteria.
After the initial history and physical
examination, patients underwent the fol-
lowing tests: complete blood count, thy-
roid hormones, serum glucose, creatinine,
hepatic enzymes, calcium, potassium, so-
dium, electrocardiography (ECG), bar-
ium enema with proctosigmoidoscopy or
colonoscopy, and study of rectal motility.
Patients with organic disease of the colon
and rectum, psychosis, hypothyroidism,
hyperparathyroidism, malignant disease,
pregnancy or lactation, or using a drug
that could produce constipation were ex-
cluded. Organic diseases of the colon, rec-
tum and anus were assumed to be absent
when digital rectal examination and bar-
ium enema or colonoscopy during the pre-
ceding year showed normal findings. Co-
lonic diverticula without signs of diverti-
culitis, however, did not lead to exclusion
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from the trial. A normal rectoanal inhibi-
tory reflex to rectal distention was pres-
ent in all patients. None of the patients
was taking any constipating medication
or had a concurrent illness associated with
constipation.
Anorectal function was assessed by
means of a side-opening water perfused
catheter connected to Albyn Medical Grif-
fon transducers and recorder. The maxi-
mum resting pressure was considered as
the highest pressure in the anal canal at
rest, recorded by the pull-through tech-
nique. The reported values are the mean
of three recordings. Squeeze pressure was
obtained by asking the patient to maxi-
mally contract the external anal sphinc-
ter while the probe was inserted through
the anal canal. There were three separate
trials and maximal pressures from each
transducer were averaged. Reflex inhibi-
tion was elicted by distending a rectal
balloon with different volumes of air. Bal-
loon distention was used to detect the
threshold (smallest volume of rectal dis-
tention) for common sensations, the first
detectable sensation (rectal sensory thres-
hold), the sensation of urgency to defe-
cate, or the sensation of pain (maximum
tolerable volume). Manometric results
were compared before and after treat-
ment period.
Patients entering the treatment phase
were randomly assigned to double blind
treatment with either 10 mg of cisapride
tid or matching placebo tablets. The Eth-
ics Committee of the General Hospital
»Sveti Duh«, Zagreb, approved the study
protocol. A written informed consent was
obtained from all patients prior to entry
in the study. Qualitative data were re-
corded as frequency and percentage, and
qualitative data as median and interval.
Statistical comparisons between groups
were made with the use of nonparametric
Mann-Whitney U test for independent
samples. Differences within the groups
were tested with Wilcoxon test.
Results
Thirty-nine patients fulfilled the defi-
nition of constipation and entered the
treatment phase. Patient data are given
in Table 1. Duration of constipation var-
ied from 2 to 16 years (median 5 years) in
the cisapride group, and from 2 to 30
years (median 5.5 years) in the placebo
group. Fifty-one percent of the patients
were regularly using laxatives. Forty-one
percent of all study patients had sponta-
neous bowel movements. This study was
a prospective, double-blind, placebo con-
trolled, randomized cross-over compari-
son of the effects of cisapride 10 mg tid or
placebo. Details about the symptoms
from the questionnaire and diary cards
during the baseline period are given in
Figure 1.
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TABLE 1







Women (N) 15 (78.9%) 14 (70.0%) 2 = 0.0744 ns
Age (yrs.) 40 (19–76) 40.5 (21–71) t = 0.1125 ns
Height (cm) 166 (150–190) 167 (157–181) t = 0.1408 ns
Weight (kg) 65 (47–95) 71.5 (50–100) t = 1.2663 ns
Smokers (N) 6 (31.6%) 6 (30.0%) 2 = 0.0577 ns
Victims of violence (N) 5 (26.3%) 6 (30.0%) 2 = 0.0101 ns
Physical activity (N) 7 (36.8%) 2 (10.0%) 2 = 2.5872 ns
The two patient groups were well
matched. Treatment was well tolerated.
Side effects were defined as any extra
sensation felt during the study and were
mild in general. The most common side
effects were blotting, abdominal cramps,
nausea, headache, dizziness and fatigue.
The number of side effects recorded per
patient per week increased from 5.65 dur-
ing the baseline phase to 13.9 during the
treatment phase in the placebo group,
and from 7.89 to 24.1 in cisapride group.
So, cisapride increased total stool frequen-
cy from 4 (1–11) to 7 (14–12) (p<0.001)
and placebo from 4 (2–10) to 6 (2–11)
(p<0.05) per week.
Cisapride increased the number of
spontaneous stools from 3 (0–7) in the
baseline phase to 7 (3–11) (p<0.001), and
placebo from 2 (0–8) to 5.5 (0–11) (p<0.01)
per week (Figure 2). Laxative consump-
tion was reduced from 2.21 doses/week
during the baseline phase to 0.37 during
the treatment phase in the cisapride
group. Twelve of 14 patients in the cisa-
pride group who had been using laxative
in the baseline period turned free from
laxatives (McNemar test, 2 =7.6923; p<
0.01). In the placebo group, three patients
turned laxative-free (non significant),
and laxative consumption was reduced
from 2.05 the in baseline phase to 1.05
doses/week in the treatment phase (Fig-
ure 3).
The effect of cisapride developed pro-
gressively during the course of treatment,
whereas placebo effects when present re-
mained constant. Straining on bo- wel
movements was decreased from 69.0% to
39.7% with cisapride (p<0.0001), and from
79% to 35% with placebo (p<0.0001).
Both cisapride and placebo decreased the
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Fig. 3. Frequency of laxative consumption dur-
ing the study.
feeling of incomplete bowel movements
from 91.7% to 37.5% (p< 0.0001) and from
82.7% to 39.2% (p< 0.0001), respectively.
There was a statistically significant dif-
ference between the groups before and at
the end of the treatment period. On cis-
apride, stool consistency showed a ten-
dency to normalize (Table 2 and Figure
4).
At the end of the treatment phase,
there was a statistically significant be-
tween-group difference in the parameters
of manometric measurements (Table 3).
The parameters of manometric measure-
ment showed different tendencies in the
study groups. In the cisapride group, most
of the manometric parameter values de-
creased after the treatment as compared
to the pretreatment values. In contrast,
in the placebo group, the majority of val-
ues increased after the treatment period
(Figure 5).
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TABLE 2







1–2 14 (11.7) 20 (14.7) t = 0.715 ns
3–5 99 (82.5) 92 (67.7) t = 2.725 p<0.01
6–7 7 (5.8) 24 (17.6) t = 2.891 p<0.01

















C = cisapride; P = placebo; W = weeks
Fig. 4. Types of stools at weeks 2 and 6 of the
study.
TABLE 3







Maximal resting anal canal
pressures (mm Hg)
44.0 (20.0–76.7) 54.5 (27.7–96.0) t = 1.7424 ns
Maximal squeeze anal canal
pressures (mm Hg)
107.3 (42.3–200.7) 152.0 (59.7–272.0) t = 1.7543 ns
Thresholds of IAS relaxation (ml) 20 (10–50) 20 (20–50) t = 0.2940 ns
Amplitude of RAIR (mm Hg) 25 (10–40) 25 (5–73) t = 0.5874 ns
Rectal sensory threshold (ml) 10 (10–30) 20 (5–30) t = 0.3734 ns
Maximum tolerable volume (ml) 200 (80–300) 160 (90–300) t = 1.0640 ns
Discussion
The majority of constipated patients
will experience symptom relief with di-
etary modification and simple osmotic
laxatives. Patients with proven pelvic
floor dysfunction (anorectal manometry,
balloon expulsion study, defecography), if
the symptoms are severe enough, should
be considered as candidates for biofeed-
back. Some of those patients who do not
respond are treated with aggressive laxa-
tive programs; however, their long-term
use causes damage to the enteric nervous
system which may prove irreversible. Re-
fractory patients could be considered for
surgery, although only few will be quali-
fied after more extensive physiologic stu-
dies1.
Cisapride has been extensively used
in the treatment of constipation, how-
ever, with controversial results11–14. Ac-
cording to Muller-Lissner, cisapride re-
duced or even discontinued laxative use,
thus interrupting the vicious circle main-
tained by laxative abuse12. Because of
concerns about its safety it was with-
drawn from the market in the USA in
July 2000. According to data published
since 1993, 30 million US residents were
taking the medication, and at the same
time it was related to 111 deaths and 270
instances of irregular heartbeat were re-
ported18, however, but we think that cis-
apride is quite safe (if accompanied with
due precaution measures). This study
was conducted to evaluate the efficacy
and side effects of short term therapy
with cisapride. The baseline phase al-
lowed for the quantification of placebo ef-
fects: placebo increased stool frequency,
changed stool consistency and reduced
laxative consumption. These effects were
maintained throughout the observed pe-
riod. In contrast, changes induced by the
active treatment effects developed pro-
gressively during the treatment phase.
Cisapride affected stool frequency and
laxative intake. Stool consistency in the
cisapride group showed a tendency to-
ward normal, and reduction in the num-
ber of laxative users was recorded. There
were no statistically significant differen-
ces between the effects of cisapride and
placebo on other symptoms and bowel
motility parameters.
In this study cisapride was not demon-
strated to be superior to placebo in con-
trolling the symptoms of constipation. It
should be borne in mind that the placebo
response was between 60% and 70%. Pla-
cebo response decreased with time. In
this study we observed a decrease in stool
frequency from week 4 to week 3 of treat-
ment with placebo. Longer studies may
obtain different results. Accordingly,
short term treatment of constipated pa-
tients with cisapride is no more effica-
cious than placebo. Therefore, prescrib-
ing cisapride for this indication over a
short period of time should better be avoi-
ded.
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C = cisapride; P = placebo; W = weeks
Fig. 5. Manometric parameters in study weeks
2 and 6 in cisapride and placebo group.
Other prokinetics have been develo-
ped with more selective actions on the co-
lon. Tegaserod and prucalopride have
shown promising results in idiopathic
chronic constipation, however, additional
studies are need to assess their toxicity
and side effects22,23.
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U^INAK CISAPRIDA NASPRAM PLACEBA I DIJETE U LIJE^ENJU
KRONI^NE KONSTIPACIJE
S A @ E T A K
U bolesnika s kroni~nom idiopatskom konstipacijom (prema Rimskim II kriteriji-
ma) ispitivan je u~inak cisaprida (10 mg tri puta na dan) na defekacijske zna~ajke,
upotrebu laksativa (dnevnik simptoma) i motilitet (manometrija anorektuma). Nakon
uvodnog razdoblja od 14 dana (I. faza) tijekom koje su svi bolesnici bili na dijeti obo-
ga}enoj vlaknima, uslijedila je II. faza (kontrolirana, randomizirana, dvostruko slijepa
faza u trajanju od 30 dana) u kojoj je jedna skupina bolesnika bila na placebu (n=20), a
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druga na cisapridu (n=19). Nakon svake faze bolesnicima je u~injena anorektalna ma-
nometrija. Nuspojave vezane za lije~enje cisapridom su bilje`ene, no nisu bile zna~aj-
nije naravi. U objema skupinama ispitanika uo~en je porast broja stolica na tjedan, i to
u skupini na cisapridu sa 4 (1–11) stolice na 11 (12–14) stolica na tjedan (p<0,001), a u
skupni na placebu sa 4 (2–10) na 6 (2–11) stolica na tjedan (p<0,05). Osje}aj napre-
zanja za vrijeme defekacije u bolesnika s konstipacijom smanjen je sa 69% na 39,7%
skupine na cisapridu (p<0,0001), a u bolesnika na placebu sa 79% na 35% skupine
(p<0,0001). U objema skupinama zabilje`en je i pad incidencije nepotpunog pra`njenja,
i to s 91,7% na 37,5% (p<0,0001) u skupini na cisapridu te s 82,7% na 39,2% (p<0,0001)
u skupini na placebu. Cisaprid je smanjio potrebu za laksativom te pokazao tendenciju
normaliziranja konzistencije stolice. Nije zabilje`en utjecaj cisaprida ili placeba na
druge simptome ili motilitetne parametre u bolesnika s idiopatskom konstipacijom.
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